Hepatorenal syndrome Medical Services in China

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure that occurs in patients with advanced liver disease—most commonly decompensated cirrhosis or acute-on-chronic liver failure—without evidence of intrinsic kidney pathology. It is not caused by structural renal damage, obstruction, or nephrotoxic injury, but rather by profound systemic and splanchnic vasodilation, leading to intense renal vasoconstriction, reduced renal perfusion, and progressive decline in glomerular filtration rate (GFR). Two main types are recognized: Type 1 HRS, characterized by rapid deterioration in renal function (doubling of serum creatinine to >2.5 mg/dL or reduction in creatinine clearance by >50% to <20 mL/min within ≤2 weeks), and Type 2 HRS, marked by more gradual, stable but subnormal renal function (serum creatinine 1.5–2.5 mg/dL), often associated with refractory ascites. Pathogenesis centers on nitric oxide–mediated splanchnic arterial vasodilation, triggering activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and endothelin pathways—culminating in intense renal cortical vasoconstriction and impaired sodium/water excretion. Epidemiologically, HRS develops in approximately 10–20% of hospitalized patients with cirrhosis and ascites over one year; among those with spontaneous bacterial peritonitis (SBP), incidence rises to 30–40%. Risk factors include severe portal hypertension, low mean arterial pressure (<80 mmHg), hyponatremia (<130 mmol/L), high Child-Pugh or MELD scores, recent large-volume paracentesis without albumin infusion, and infections—especially SBP. HRS profoundly impairs quality of life: patients experience debilitating fatigue, anorexia, confusion (hepatic encephalopathy), dyspnea from fluid overload, and profound anxiety related to prognosis and treatment uncertainty. Without intervention, median survival for Type 1 HRS is less than 2 weeks; even with pharmacologic therapy, 3-month mortality exceeds 50%. The condition imposes substantial psychosocial burden—limiting mobility, disrupting employment and family roles, and necessitating frequent hospitalizations. Early recognition and multidisciplinary management involving hepatology, nephrology, and critical care are essential. While liver transplantation remains the only definitive cure, timely diagnosis and bridge therapies (e.g., terlipressin + albumin) can stabilize renal function and improve transplant candidacy. Patient education, nutritional support, and palliative integration are vital components of holistic care in advanced disease.

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure occurring in patients with advanced liver disease—most commonly decompensated cirrhosis or acute-on-chronic liver failure—without intrinsic kidney pathology. It is characterized by intense renal vasoconstriction, reduced glomerular filtration rate (GFR), sodium retention, and progressive azotemia, despite preserved renal histology. HRS is classified into two types: Type 1 (rapidly progressive, doubling of serum creatinine to >2.5 mg/dL within ≤2 weeks) and Type 2 (more indolent, with stable but elevated creatinine [1.5–2.5 mg/dL], often associated with refractory ascites). Early recognition and multidisciplinary intervention are critical, as untreated Type 1 HRS carries a median survival of <2 weeks.

Conservative treatment forms the cornerstone of initial management and focuses on optimizing systemic hemodynamics and minimizing nephrotoxic insults. Strict avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics (especially high-dose loop diuretics), and contrast media is mandatory. Volume expansion with albumin (1.0–1.5 g/kg on day 1, followed by 20–40 g/day) is essential—not only to counteract intravascular underfilling but also to improve effective arterial blood volume and attenuate neurohormonal activation (e.g., renin-angiotensin-aldosterone system and sympathetic nervous system). Paracentesis for large-volume ascites removal (>5 L) must be accompanied by intravenous albumin infusion (6–8 g/L of ascites removed) to prevent post-paracentesis circulatory dysfunction. Nutritional support—including adequate caloric intake (30–35 kcal/kg/day) and protein supplementation (1.2–1.5 g/kg/day, adjusted for hepatic encephalopathy)—is vital to mitigate catabolism and preserve renal perfusion. Close monitoring of serum electrolytes, creatinine, urine output, and mean arterial pressure guides fluid balance and prevents hyponatremia-induced cerebral edema or hypotension-induced renal hypoperfusion.

Pharmacologic therapy targets reversal of splanchnic vasodilation and subsequent renal vasoconstriction. Vasoconstrictors—particularly terlipressin—are first-line in most international guidelines (including EASL and AASLD) for Type 1 HRS. Terlipressin (initial dose 0.5–1 mg IV every 4–6 hours, titrated up to 2 mg every 4 hours based on creatinine response and systolic BP) improves renal perfusion by activating V1 receptors on splanchnic arterioles, thereby increasing systemic vascular resistance and cardiac preload. Its efficacy is significantly enhanced when combined with albumin. In regions where terlipressin is unavailable (e.g., the United States), norepinephrine (0.05–0.3 μg/kg/min IV) or midodrine plus octreotide (12.5–25 mg PO TID + 100 μg SC TID) may be used, though evidence supporting these regimens is less robust. Antibiotic prophylaxis (e.g., norfloxacin 400 mg daily or ciprofloxacin 500 mg daily) is indicated in patients with ascites and low ascitic fluid protein (<1.5 g/dL) to reduce spontaneous bacterial peritonitis—a major precipitant of HRS. Lactulose and rifaximin are employed to manage hepatic encephalopathy, which can exacerbate hemodynamic instability.

Surgical and procedural interventions are definitive but highly selective. Liver transplantation remains the only curative treatment for HRS, with 1-year post-transplant survival exceeding 70% in carefully selected candidates. Pre-transplant HRS increases perioperative risk but does not preclude transplantation; indeed, early listing is strongly recommended upon diagnosis. Transjugular intrahepatic portosystemic shunt (TIPS) may be considered in select patients with Type 2 HRS and well-preserved synthetic liver function (Child-Pugh A/B, MELD <18), as it reduces portal hypertension and improves renal hemodynamics in ~50% of cases. However, TIPS is contraindicated in overt hepatic encephalopathy, severe cardiopulmonary disease, or MELD ≥18 due to increased mortality risk. Renal replacement therapy (RRT)—including continuous venovenous hemofiltration (CVVH) or intermittent hemodialysis—is reserved for life-threatening complications (e.g., hyperkalemia, pulmonary edema, or uremic symptoms) and serves as a bridge to transplantation rather than definitive therapy. Extracorporeal albumin dialysis (e.g., molecular adsorbent recirculating system, MARS) has shown transient improvement in renal and hepatic parameters in small studies but lacks robust evidence for mortality benefit and is not routinely recommended outside clinical trials.

China offers distinct advantages in the comprehensive management of HRS. First, integrated hepatorenal care pathways—coordinated between hepatology, nephrology, transplant surgery, and critical care—are increasingly standardized across Tier-3 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital), enabling rapid diagnostic workup and protocol-driven initiation of terlipressin-albumin therapy. Second, China’s National Medical Products Administration (NMPA) approved terlipressin in 2021, ensuring timely access without reliance on compassionate-use programs. Third, China leads globally in liver transplantation volume, performing over 6,000 procedures annually, with expanding use of extended-criteria donors and donation after circulatory death (DCD), shortening wait times. Fourth, innovative supportive therapies—including real-time point-of-care ultrasound-guided fluid assessment, AI-enhanced MELD scoring, and standardized nutritional rehabilitation protocols—are widely implemented in major centers. Finally, cost-effectiveness is notable: terlipressin and albumin regimens are substantially more affordable than in Western countries, and national health insurance covers ≥70% of transplant-related expenses for eligible patients.

Recovery and long-term prognosis hinge on sustained liver function improvement and prevention of recurrence. Patients achieving HRS reversal must undergo rigorous etiologic evaluation (e.g., viral hepatitis serology, autoimmune markers, genetic testing for Wilson disease or hemochromatosis) and receive targeted antiviral or immunomodulatory therapy where indicated. Lifelong abstinence from alcohol and avoidance of hepatotoxic agents are non-negotiable. Post-reversal, patients require quarterly nephrology follow-up including eGFR estimation (CKD-EPI equation), urinary NGAL or KIM-1 biomarkers (where available), and Doppler renal ultrasound to assess resistive index. Dietary sodium restriction (<2 g/day) and careful diuretic titration (spironolactone ± furosemide) are maintained under nephrology supervision. Vaccination against hepatitis A/B, influenza, and pneumococcus is strongly advised. Psychosocial support—including counseling and peer-led patient education groups—improves adherence and reduces hospital readmission. Importantly, even after apparent recovery, patients remain at lifelong risk for HRS recurrence; thus, any episode of infection, GI bleeding, or rapid diuresis warrants immediate nephrology consultation. With coordinated, guideline-concordant care—particularly in high-volume Chinese centers—the trajectory of HRS has shifted from uniformly fatal to potentially reversible, offering meaningful survival extension and improved quality of life.